HC Wainwright Brokers Lower Earnings Estimates for LPTX

Leap Therapeutics, Inc. (NASDAQ:LPTX) – Investment analysts at HC Wainwright dropped their Q1 2025 earnings per share estimates for shares of Leap Therapeutics in a report issued on Thursday, March 27th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of ($0.38) for the quarter, down from their previous estimate of ($0.34). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Leap Therapeutics’ current full-year earnings is ($1.84) per share. HC Wainwright also issued estimates for Leap Therapeutics’ Q2 2025 earnings at ($0.35) EPS, Q3 2025 earnings at ($0.29) EPS, Q4 2025 earnings at ($0.24) EPS, FY2025 earnings at ($1.26) EPS, FY2026 earnings at ($0.87) EPS, FY2027 earnings at ($0.80) EPS, FY2028 earnings at ($0.91) EPS and FY2029 earnings at ($0.37) EPS.

Several other equities research analysts also recently weighed in on the stock. Robert W. Baird downgraded shares of Leap Therapeutics from an “outperform” rating to a “neutral” rating and lowered their target price for the company from $9.00 to $1.25 in a research note on Wednesday, January 29th. Baird R W downgraded Leap Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, January 29th.

Leap Therapeutics Stock Performance

NASDAQ:LPTX opened at $0.31 on Monday. The company’s 50-day simple moving average is $0.64 and its 200-day simple moving average is $2.14. Leap Therapeutics has a fifty-two week low of $0.28 and a fifty-two week high of $4.79. The stock has a market capitalization of $11.69 million, a P/E ratio of -0.16 and a beta of 0.35.

Leap Therapeutics (NASDAQ:LPTX) last issued its quarterly earnings data on Wednesday, March 26th. The company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.02.

Hedge Funds Weigh In On Leap Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of LPTX. Gilead Sciences Inc. purchased a new position in shares of Leap Therapeutics during the fourth quarter worth $15,293,000. Point72 Asset Management L.P. purchased a new position in shares of Leap Therapeutics during the 4th quarter valued at about $4,025,000. Key Client Fiduciary Advisors LLC raised its stake in shares of Leap Therapeutics by 12.2% during the 4th quarter. Key Client Fiduciary Advisors LLC now owns 361,253 shares of the company’s stock valued at $1,039,000 after buying an additional 39,330 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Leap Therapeutics by 18.0% in the 3rd quarter. Geode Capital Management LLC now owns 329,291 shares of the company’s stock valued at $847,000 after buying an additional 50,194 shares during the period. Finally, BIT Capital GmbH boosted its stake in shares of Leap Therapeutics by 248.2% in the fourth quarter. BIT Capital GmbH now owns 282,008 shares of the company’s stock worth $811,000 after buying an additional 201,008 shares during the last quarter. Institutional investors and hedge funds own 30.46% of the company’s stock.

Leap Therapeutics Company Profile

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.